1. Repositório Institucional da UFMG
  2. Publicações Científicas e Culturais
  3. Artigo de Periódico
Please use this identifier to cite or link to this item: http://hdl.handle.net/1843/56584
Full metadata record
DC FieldValueLanguage
dc.creatorMichael Ruberson Ribeiro da Silvapt_BR
dc.creatorJéssica Barreto Ribeiro dos Santospt_BR
dc.creatorAlessandra Maciel Almeidapt_BR
dc.creatorAlexander Itriapt_BR
dc.creatorAdriana Maria Kakehasipt_BR
dc.creatorJuliana Alvares Teodoropt_BR
dc.creatorFrancisco de Assis Acurciopt_BR
dc.date.accessioned2023-07-18T16:46:21Z-
dc.date.available2023-07-18T16:46:21Z-
dc.date.issued2019-
dc.citation.volume5pt_BR
dc.citation.issue2pt_BR
dc.identifier.doihttps://doi.org/10.4155/fsoa-2018-0101pt_BR
dc.identifier.issn2056-5623pt_BR
dc.identifier.urihttp://hdl.handle.net/1843/56584-
dc.description.resumoAim: To evaluate the persistence of biological (TNF inhibitor [anti-TNF]) and synthetic (conventional syntheticdisease-modifyingantirheumaticdrugs[csDMARDs])antirheumaticagentsforpsoriaticarthritisand their associated factors. Methods: A historical cohort was developed. Persistence and associated factors wereevaluatedat6and12months.Results:Atotalof161patientswereincluded.Theanti-TNFtreatment presented higher persistence as compared with csDMARDs at 6 (83.4 vs 50.8%; p < 0.05) and 12 months (66.4vs35.6%;p<0.05).Fromanti-TNFs,adalimumabandetanerceptpresentedsimilarpersistence,along with leflunomide and methotrexate among the csDMARDs. The factors associated with non-persistence withregardtoanti-TNFagentswerefemalesexanduseofinfliximab.Conclusion:Anti-TNFagentsareimportanttherapeuticalternativesand presentlowerratesofdiscontinuationascomparedwithcsDMARDs. Lay abstract: Conventional synthetic disease-modifying antirheumatic drugs (csDMARD) and anti-TNF agents were included in the Brazilian National Health System in 2009, yet were not previously the target of evaluations in a Brazilian context. Persistence, that is the time between starting and discontinuing the drug, is a proxy of effectiveness and safety for antirheumatic agents. This study evaluated medication persistence and relevant factors associated with it. Patients using infliximab showed a lower medication persistence when compared with adalimumab and etanercept. The medication persistence with anti-TNF agents was higher when compared with csDMARDs. Female sex and infliximab were predictors of medication non-persistence.pt_BR
dc.languageporpt_BR
dc.publisherUniversidade Federal de Minas Geraispt_BR
dc.publisher.countryBrasilpt_BR
dc.publisher.departmentFAR - DEPARTAMENTO DE FARMÁCIA SOCIALpt_BR
dc.publisher.departmentMED - DEPARTAMENTO DE APARELHO LOCOMOTORpt_BR
dc.publisher.departmentMED - DEPARTAMENTO DE CLÍNICA MÉDICApt_BR
dc.publisher.initialsUFMGpt_BR
dc.relation.ispartofFuture Science OApt_BR
dc.rightsAcesso Abertopt_BR
dc.subjectAntirheumatic agentspt_BR
dc.subjectMedication persistencept_BR
dc.subjectPsoriatic arthritispt_BR
dc.subject.otherAgentes anti-reumaticospt_BR
dc.subject.otherMedicamentospt_BR
dc.titleMedication persistence for psoriatic arthritis in a Brazilian real-world settingpt_BR
dc.typeArtigo de Periódicopt_BR
dc.url.externahttps://www.future-science.com/doi/10.4155/fsoa-2018-0101pt_BR
dc.identifier.orcidhttps://orcid.org/0000-0003-2550-7249pt_BR
dc.identifier.orcidhttps://orcid.org/0000-0002-5528-0658pt_BR
dc.identifier.orcidhttps://orcid.org/0000-0003-0138-9401pt_BR
dc.identifier.orcidhttps://orcid.org/0000-0001-7500-0230pt_BR
dc.identifier.orcidhttps://orcid.org/0000-0001-9411-7493pt_BR
dc.identifier.orcidhttps://orcid.org/0000-0002-0210-0721pt_BR
dc.identifier.orcidhttps://orcid.org/0000-0002-5880-5261pt_BR
Appears in Collections:Artigo de Periódico

Files in This Item:
File Description SizeFormat 
Medication persistence for psoriatic arthritis in a Brazilian real-world setting.pdf183.85 kBAdobe PDFView/Open
Show simple item record


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.